Skip to main content

Don S. Dizon, MD

Formulary Frontlines®
07/20/2018
Sarah M Temkin, MD, and Don Dizon, MD, discuss the benefits of PARP inhibitors for treating ovarian cancer and why effectiveness, toxicity, safety, and cost must be balanced for an individual patient to determine the right PARP inhibitor for...
Sarah M Temkin, MD, and Don Dizon, MD, discuss the benefits of PARP inhibitors for treating ovarian cancer and why effectiveness, toxicity, safety, and cost must be balanced for an individual patient to determine the right PARP inhibitor for...
Sarah M Temkin, MD, and Don...
07/20/2018
First Report Managed Care
Perspectives
08/07/2023
Elizabeth Donckels, MSPH, and colleagues investigate several measurement tactics to promote cancer care quality improvement for transgender individuals.
Elizabeth Donckels, MSPH, and colleagues investigate several measurement tactics to promote cancer care quality improvement for transgender individuals.
Elizabeth Donckels, MSPH, and...
08/07/2023
Journal of Clinical Pathways